{"id":"W3130253087","doi":"10.1158/1078-0432.ccr-20-4338","title":"FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Canada","funders":"U.S. Food and Drug Administration; National Institutes of Health","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Chemotherapy; Cancer; Lung cancer; Internal medicine; Immunotherapy; Intensive care medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008568355,0.0009029188,0.0009024136,0.002339039,0.0006990516,0.002846302,0.0011126,0.004105603,0.0159955],"category_scores_gemma":[0.007526379,0.0003402558,0.001185056,0.001884466,0.0006250416,0.001290263,0.0006274033,0.002286629,0.008006864],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003190555,"about_ca_system_score_gemma":0.01085437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00665113,"about_ca_topic_score_gemma":0.0143356,"domain_scores_codex":[0.9961358,0.001049526,0.0003659474,0.0003491751,0.00184695,0.0002525837],"domain_scores_gemma":[0.9920924,0.001144434,0.001215937,0.0001841867,0.004714449,0.0006485995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000217782,0.00006503895,0.0002892739,0.003508546,0.00006273457,0.0001314985,0.00004256735,0.0001000403,0.000905947,0.002690304,0.7848227,0.2071635],"study_design_scores_gemma":[0.0002326021,0.0001858118,0.001745641,0.002350869,0.000092815,0.000154833,0.00002663758,0.00006418883,0.000215507,0.0003811831,0.9945384,0.00001143636],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004538642,0.6307847,0.002036119,0.09147292,0.02842615,0.003245738,0.006446415,0.0007185874,0.2323307],"genre_scores_gemma":[0.03667402,0.5484794,0.005820181,0.106248,0.01751114,0.003307216,0.009697976,0.0002908329,0.2719712],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.0159955,"threshold_uncertainty_score":0.05351031,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1427796876373779,"score_gpt":0.5034665726369157,"score_spread":0.3606868849995378,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}